Hutchison China MediTech Limited Stock London S.E.
Stocks
KYG4672N1198
Pharmaceuticals
OTC Markets Traded| Market Cap | 1.9B 0 1.67B 1.56B 1.43B 2.68B 183B 2.72B 18.47B 7.22B 90.15B 7.15B 6.99B 312B | P/E 2026 * |
35.8x | P/E 2027 * | 33.9x |
|---|---|---|---|---|---|
| Enterprise Value | 987M 0 867M 806M 739M 1.39B 95.01B 1.41B 9.57B 3.74B 46.71B 3.7B 3.62B 162B | EV / Sales 2026 * |
1.56x | EV / Sales 2027 * | 1.28x |
| Free-Float |
61.2% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Hutchison China MediTech Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Chig Fung Cheng
CEO | Chief Executive Officer | 59 | 2025-08-24 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 61 | 2021-12-31 |
Karen Atkin
COO | Chief Operating Officer | 60 | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Edith Shih
BRD | Director/Board Member | 74 | 2005-12-31 |
Chig Fung Cheng
BRD | Director/Board Member | 59 | 2010-12-31 |
Wei Guo Su
BRD | Director/Board Member | 68 | 2017-03-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 1.97B | |
| +0.86% | +1.43% | +48.50% | +160.39% | 1,057B | |
| +1.59% | +4.09% | +55.34% | +53.96% | 624B | |
| +0.95% | +1.91% | +35.91% | +81.14% | 454B | |
| +1.60% | +6.25% | +33.95% | +29.84% | 341B | |
| -0.60% | +1.52% | +35.68% | +39.76% | 297B | |
| -0.14% | +0.60% | +16.17% | +17.53% | 262B | |
| +0.09% | -2.82% | -28.29% | -41.71% | 215B | |
| +1.22% | +2.66% | +21.87% | +59.73% | 201B | |
| -1.18% | -3.70% | +14.23% | +66.51% | 162B | |
| Average | +0.33% | +1.26% | +25.93% | +51.91% | 401.55B | |
| Weighted average by Cap. | +0.54% | +1.92% | +35.73% | +77.61% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 631M 0 554M 515M 473M 889M 60.76B 902M 6.12B 2.39B 29.87B 2.37B 2.32B 103B | 717M 0 630M 586M 538M 1.01B 69.09B 1.03B 6.96B 2.72B 33.96B 2.69B 2.64B 117B |
| Net income | 47.77M 0 41.95M 39.02M 35.8M 67.27M 4.6B 68.31M 463M 181M 2.26B 179M 175M 7.82B | 63.36M 0 55.65M 51.75M 47.49M 89.22M 6.1B 90.6M 615M 240M 3B 238M 233M 10.37B |
| Net Debt | -918M -0 -806M -749M -688M -1.29B -88.36B -1.31B -8.9B -3.48B -43.44B -3.44B -3.37B -150B | -987M -0 -867M -806M -740M -1.39B -95.07B -1.41B -9.58B -3.74B -46.74B -3.71B -3.63B -162B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
